Oppenheimer Downgrades Imperva (IMPV) to Perform

Go back to Oppenheimer Downgrades Imperva (IMPV) to Perform

Sterne Agee Upgrades Imperva (IMPV) to Buy

April 11, 2014 7:04 AM EDT

Sterne Agee upgraded Imperva (NYSE: IMPV) from Neutral to Buy with a price target of $35.00 (unchanged).

For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.

Shares of Imperva closed at $28.00 yesterday.

... More

Deutsche Bank Downgrades Imperva (IMPV) to Hold

April 10, 2014 8:55 AM EDT

Deutsche Bank downgraded Imperva (NYSE: IMPV) from Buy to Hold with a price target of $40.00 (from $60.00).

Analyst Nandan Amladi said, "IMPV negatively preannounced its Q114 numbers, guiding down its Rev and EPS. It now expects Rev/ EPS of $31.0m - $31.5m / ($0.40) ($0.44) vs prior guide of $36.0 - $37.0m/... More

Imperva, Inc. (IMPV) Warns for Q1

April 9, 2014 4:08 PM EDT

Imperva, Inc. (NYSE: IMPV) expects to report total revenue for the first quarter of 2014 in the range of $31.0 million to $31.5 million compared to the companys prior guidance of total revenue in the range of $36.0 million to $37.0 million. The consensus is $36.7 million.

Imperva also expects to report non-GAAP operating loss in the first quarter of 2014 in the range of $(9.5) million to $(10.5) million, and expects to report non-GAAP net loss per share attributable to Imperva stockholders in the range of $(0.40) to $(0.44) using approximately 25.2 million... More